Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Qatar University | OTHER |
| Qatar Foundation | UNKNOWN |
| Qatar Diabetes Association | UNKNOWN |
| Qatar Supreme Council of Health |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of the study is to pilot-phase test the effectiveness of the microclinic social induction model and its effects on behavioral and metabolic outcomes in different levels of social and familial relationships in Qatar. The investigators novel microclinic model is based on the principle that both healthy and unhealthy behaviors spread through preexisting social networks. A microclinic is a small group of approximately 2-8 friends or family members who are taught to modify their own behaviors as well as the behaviors of those around them, with a particular focus on the four "M's": Meals, Movement, Monitoring, and Medication. More than social support groups or peer-to-peer interventions, the microclinic model is unique in its focus on the long-term propagation of healthy behaviors throughout a participant's entire social network. Qatar is uniquely positioned (with its central geographic location in the Gulf region and its leadership in science and education) to spearhead a regional intervention focused on managing and preventing diabetes in the Gulf region.
This pilot study, "Microclinic Social Induction Intervention for Diabetes and Obesity Management in Qatar," is a two-arm randomized controlled trial of a 7-week condensed intervention to evaluate the efficacy of the microclinic social induction model on propagating lifestyle changes and in improving glycemic and metabolic control in Doha, Qatar.
The microclinic social induction model leverages different levels of social and familial relationships to positively influence behaviors relating to diabetes and other metabolic conditions through small treatment units called 'microclinic groups,' consisting of 2-8 peers and family members of the same social network. The intervention model brings microclinic groups to a larger classroom network (~25 people/class) where each class shares access to a culturally salient diabetes educational curriculum and group support to promote health behavior changes such as improvement in diet, exercise, medication adherence, and blood pressure management to then influence better glycemic and metabolic control.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Microclinic social induction training | Experimental | BMI of 30 and over; or BMI of 25 and over and self-reported pre-diabetes or type II diabetes will receive the Microclinic Social Induction Diabetes and Obesity Program. The intervention is a training on diabetes self-management, disease monitoring, diabetes prevention, prevention of complications, health behavior change, and social network supports in order to improve chronic disease risk factors. |
|
| Controls | No Intervention | Receiving no intervention but parallel primary and secondary outcome measures as intervention study arm |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Microclinic Social Induction Diabetes and Obesity Program | Behavioral | Microclinics consist of 2-8 individuals from pre-existing social networks (friends, relatives, coworkers, neighbors, etc) that voluntarily participate in ongoing education and medical monitoring from local health care professionals, learning and practicing diabetes management strategies, sharing much-needed medical supplies, and exchanging social support. |
| Measure | Description | Time Frame |
|---|---|---|
| Weight | Change in body weight (and BMI) | Weekly measurements between baseline and end of trial after 7 weeks |
| HbA1c | Change in HbA1c from baseline to end of 7-week pilot phase. | Baseline, end of trial after 7 weeks |
| Waist circumference | Baseline, 4th-week midpoint, 7th-week final |
| Measure | Description | Time Frame |
|---|---|---|
| Blood Pressure | Systolic and diastolic blood pressure changes | Baseline, 4th-week midpoint, 7th-week final |
| Health Profile Survey | Change in overall health seeking and health maintenance behaviors. |
| Measure | Description | Time Frame |
|---|---|---|
| Social Network Relationships | Changes in degree of interpersonal health support relationships as assess on Social Network Matrix instrument | Baseline, end of trial after 7 weeks. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Eric L Ding, PhD | Harvard School of Public Health (HSPH) | Principal Investigator |
| Daniel Zoughbie, DPhil | Microclinic International | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Qatar Diabetes Association | Doha | Qatar |
Not provided
| UNKNOWN |
| Harvard School of Public Health (HSPH) | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Baseline, end of trial after 7 weeks. |
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| D050177 | Overweight |
| D009765 | Obesity |
| D006973 | Hypertension |
| D002908 | Chronic Disease |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D001835 | Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
Not provided
Not provided